Sai Life Sciences IPO

Sai Life Sciences Ltd

₹14,094 /27 sharesMinimum Investment

Sai Life Sciences IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
--₹549.00₹650.00₹101.00 (18.40%)

Sai Life Sciences IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
11 Dec ‘24 - 13 Dec ‘24₹14,09427₹522 - ₹549
Issue SizeIPO Doc
3042.62Cr
RHP PDF

Subscription rate

As of 13 Dec'24, 04:00 PM
Qualified Institutional Buyers12.05x
Non-Institutional Investor2.74x
Retail Individual Investor0.78x
Total4.30x

About Sai Life Sciences

Sai Life Sciences is a contract research, development, and manufacturing organisation (CRDMO) that caters to global pharmaceutical innovators and biotechnology companies. The company offers services spanning the entire drug discovery, development, and manufacturing process for small molecule new chemical entities (NCEs). The company’s CDMO portfolio features over 170 innovator pharmaceutical products, with 38 of these products supporting the manufacturing of 28 commercial drugs.;
Founded in
1999
Managing director
Mr. Krishnam Raju Kanumuri
Parent organisation
Sai Life Sciences Ltd

Strengths & Financials of Sai Life Sciences

Strengths
Risks
During FY24 and the six months ending September 30, 2024, the company served over 280 and 230 innovator pharmaceutical companies, respectively, including 18 of the top 25 global pharmaceutical companies (in terms of revenue for the calendar year 2023). Its services cater to regulated markets such as the US, UK, Europe, and Japan.
Over the past five years and through September 30, 2024, Sai Life Sciences has supported more than 200 small molecule discovery programs. In the last three years and six months, the company has collaborated with over 160 customers.
The company claims to have implemented energy conservation initiatives in production, utilities, and effluent treatment. In FY24, it centralised air compression, installed energy-efficient pumps, and significantly increased the use of renewable energy at its Unit IV in Bidar to 89%, up from 67% in FY22, resulting in reduced carbon dioxide emissions.
Its manufacturing facilities have received certifications from major regulatory bodies, including the United States Food and Drug Administration (USFDA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), and India’s Central Drug Standards Control Organisation (CDSCO).
Sai Life Sciences claims to be among the few Indian CRDMOs that integrate discovery and development operations across the US, UK, and India, coupled with manufacturing capabilities located in India.
Sai Life Sciences states that the company strategically operates near key innovation clusters, with facilities in Greater Boston and Manchester. These locations provide access to cutting-edge research, a skilled global workforce, and collaboration opportunities within innovation ecosystems. Additionally, the company's facilities in India offer a cost-effective advantage, enabling large-scale drug discovery, development, and commercial production.
The company has seen a consistent increase in revenue from operations and profit after tax (PAT). Revenue from operations increased from Rs 869.59 crore in FY22 to Rs 1,217.14 crore in FY23 to Rs 1,465.18 crore in FY24. PAT increased from Rs 6.23 crore in FY22, to Rs 9.99 crore in FY23 to Rs 82.81 crore in FY24

Sai Life Sciences Financials

*All values are in Rs. Cr
No Graph Data To Display

Application Details of Sai Life Sciences IPO

Apply asPrice bandApply upto
Regular522 - 549₹2 Lakh
High Networth Individual522 - 549₹2 - 5 Lakh
For Sai Life Sciences IPO, eligible investors can apply as Regular.
ⓒ 2016-2025 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 5.6.6
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  IDFC |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ

ABOUT GROWW